JUN 0 9 1008 E INSTHE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

YANG et al. Atty. Ref.: 4410-7

Serial No. 10/543,091 TC/A.U.: 1614

Filed: July 22, 2005 Examiner: TBA

For: ALANINE COMPOUNDS, THE METHODS OF PREPARING THEM

AND THEIR USE

June 9, 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Listed on accompanying Form PTO/SB/08a is information that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. At least one of the boxes below applies to the present application:

- 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.
 - a. Contingent Request to Treat Under 37 C.F.R. § 1.97(c)

 In the event a first Office Action has been mailed prior to filing of the present Information Disclosure Statement and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(c) and charge the

undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p). The present paper is submitted in duplicate for this purpose.

b. Contingent Request to Treat Under 37 C.F.R. § 1.97(e)(1)
In the event a first Office Action has been mailed prior to the filing of the present Information Disclosure Statement, and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(e)(1) in that the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

b.1. Patent Term Adjustment

I hereby certify that each item of information was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in Section 1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement. 37 C.F.R. §1.704(d).

c. Contingent Request to Treat Under 37 C.F.R. § 1.97(e)(2)

In the event a first Office Action has been mailed prior to the filing of the present Information Disclosure Statement, and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(e)(2) in that the undersigned hereby states that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my

knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
 - a. I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1). Contingent Request Under 37 C.F.R. § 1.97(d). In the event a Notice of Allowance or a Final Rejection has been mailed prior to filing this Information Disclosure Statement, the Office is authorized to treat this as a submission under 37 C.F.R. 1.97(d) and charge the undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p). The present paper is submitted in duplicate for this purpose.

a.1. Patent Term Adjustment


I hereby certify that each item of information was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in Section 1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement. 37 C.F.R. §1.704(d).

b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this



Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2). Attached is our check in the amount of \$ in payment of the fee under 37 C.F.R. § 1.17(p). This Information Disclosure Statement is being filed more than three 3. months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee 37 C.F.R. § 1.97(d). It is hereby requested that the Information Disclosure Statement be considered. Attached is our check in the amount of \$ in payment of the fee under 37 C.F.R. § 1.17(i). I hereby state that each item of information contained in this a. Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1). a.1. Patent Term Adjustment I hereby certify that each item of information was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in Section 1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement. 37 C.F.R. §1.704(d). b. I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).





It is respectfully requested that the Examiner initial and return a copy of the enclosed PTOPTO/SB/08a, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 14-1140 referencing docket number 4410-7.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Paul T. Bowen Reg. No. 38,009

PTB:lmr

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

Sheet 1	of 1					PTO/SB	/08á
INFORMATION DISCLOSURE		ATTY. DOC	ATTY. DOCKET NO.				
	CITATION	4410-7		10/543,091			
			APPLICANT		· · · · · · · · · · · · · · · · · · ·		
	_	VANG	YANG et al.				
(Use several sheets if necessary)			FILING DATE				
				tc/a.u. 1614			
		July 22,	July 22, 2005				
PART		U.S.	PATENT DOCUMENTS				
*EXAMINE ROE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
	4,816,484	03/1989	TOYOSHIMA et al.	.			
		 					
	+						
					-		
		<u> </u>			<u> </u>		
		FOREIC	GN PATENT DOCUMENTS			TRANSI	ATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	0196222	01/1986	EP			х	
	1243577	09/2002	EP			х	
	2000-344748	12/2000	ЛР			ABSTRACT	
	OTHER DOCL	I JMENTS (inclu	ıding Author, Title, Date, Pertii	nent pages, e	tc.)	Ll	
			EP03815509 (02/2006) 2 pgs.	nom pagos, s		V	
	TAKESADA et al., "Str	ructure Determin	ation of Metabolites Isolated from I				
		enylalanine-Deri	vative Hypoglycemic Agent," Bioo	rganic & Medic	inal Chemist	ry, Vol. 4	, No. 1
	(1996), pp. 1771-1781					-	
			. —			-	-

*Examiner	 Date Considered	